TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20518171
Drug: Transcutaneous electrical
Normalized name: Transcutaneous Electrical Nerve Stimulators (TENS Units) MISCELL EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcutaneous electrical acupoint stimulation (TEAS) combined with auricular acupoint sticking (AAS), treated once each day for 15 days, with 3 courses of treatment evaluated after 45 days.
Study: 17335683
Drug: Treatment algorithms
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment algorithms based on published data and clinical experience
Study: 2105673
Drug: 9 mg
Normalized name: fiber 469 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9 mg naltrexone
Study: 7262174
Drug: Commercial capsule
Normalized name: iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Commercial capsule containing 50 mg of ketoprofen
Study: 7262174
Drug: Simple capsule
Normalized name: Monistat Simple Therapy
DrugBank: Octisalate (DB11062)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simple capsule containing 50 mg of ketoprofen
Study: 7262174
Drug: Commercial capsule
Normalized name: iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Commercial capsule taken 6 hourly for thirteen doses
Study: 7674700
Drug: Ketoprofen solution
Normalized name: Ketoprofen
DrugBank: Ketoprofen (DB01009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketoprofen solution
Study: 7262174
Drug: Commercial capsule
Normalized name: iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Commercial capsule
Study: 7262174
Drug: Simple capsule
Normalized name: Monistat Simple Therapy
DrugBank: Octisalate (DB11062)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simple capsule
Study: 19652072
Drug: Sunitinib 37.5
Normalized name: sunitinib 37.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunitinib 37.5 mg/d (AM dosing)
Study: 19652072
Drug: Sunitinib 37.5
Normalized name: sunitinib 37.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunitinib 37.5 mg/d (PM dosing)
Study: 8653998
Drug: Interferon alfa‐2b
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon alfa‐2b (2 or 10 MU/m2/day SQ for 3 days) concurrent with etoposide
Study: 8653998
Drug: Etoposide (75,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etoposide (75, 100, or 125 mg/m2/day)
Study: 6299093
Drug: m-AMSA 120
Normalized name: m-AMSA
DrugBank: Amsacrine (DB00276)
Approvals — FDA: no, EMA: no, PMDA: no
Description: m-AMSA 120 mg/m2 intravenously every 3 weeks
Study: 6299093
Drug: neocarzinostatin 2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: neocarzinostatin 2.0 mg/m2 intravenously daily X 5 every 4 weeks
Study: 30829505
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy integrated with motivational interviewing
Study: 17171458
Drug: Intensive behavioral
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive behavioral day treatment plus housing contingent on drug abstinence
Study: 17171458
Drug: Intensive behavioral
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive behavioral day treatment plus housing not contingent on abstinence
Study: 17171458
Drug: Intensive behavioral
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive behavioral day treatment plus no housing
Study: 15080765
Drug: Sublingual buprenorphine
Normalized name: buprenorphine Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual buprenorphine solution 32 mg
Study: 15080765
Drug: Sublingual buprenorphine
Normalized name: buprenorphine Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual buprenorphine tablet 16 mg
Study: 15080765
Drug: Sublingual buprenorphine/naloxone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual buprenorphine/naloxone tablet 16/4 mg
Study: 15080765
Drug: Sublingual buprenorphine
Normalized name: buprenorphine Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual buprenorphine solution (all doses)
Study: 15080765
Drug: Sublingual buprenorphine
Normalized name: buprenorphine Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual buprenorphine 16 mg tablet with naloxone
Study: 11220254
Drug: Esmolol (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esmolol (2 mg/kg)
Study: 9685762
Drug: 0.05 percent
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05 percent sodium fluoride and 0.12 percent chlorhexidine rinses, daily from the end of the sixth month of pregnancy until delivery
Study: 7988301
Drug: 3.5 mg
Normalized name: niacin 13.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.5 mg M1 intravenously
Study: 7988301
Drug: 3.5 mg
Normalized name: niacin 13.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.5 mg M2 intravenously
Study: 7988301
Drug: 3.5 mg
Normalized name: niacin 13.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.5 mg glibenclamide (Gb) intravenously
Study: 7988301
Drug: 3.5 mg
Normalized name: niacin 13.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.5 mg glibenclamide (Gb) orally
Study: 3058290
Drug: Alprazolam (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alprazolam (mean daily dose 3.34 mg)
Study: 3058290
Drug: Desipramine (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desipramine (mean daily dose 192 mg)
Study: 29174961
Drug: Butorphanol (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Butorphanol (0.4 mg kg−1)
Study: 29174961
Drug: Methadone (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methadone (0.3 mg kg−1)
Study: 23841572
Drug: Plant stanol
Normalized name: plant stanol ester
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plant stanol esters (staest) - 3.0 g of plant stanols/d
Study: 17679633
Drug: Problem-solving treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Problem-solving treatment (n = 105)
Study: 15086170
Drug: Polidocanol injection
Normalized name: polidocanol Injection
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Polidocanol injection therapy
Study: 12438291
Drug: Darusentan 30
Normalized name: Darusentan
DrugBank: Darusentan (DB04883)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Darusentan 30 mg/d
Study: 12438291
Drug: Darusentan 100
Normalized name: Darusentan
DrugBank: Darusentan (DB04883)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Darusentan 100 mg/d
Study: 12438291
Drug: Darusentan 300
Normalized name: Darusentan
DrugBank: Darusentan (DB04883)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Darusentan 300 mg/d
Study: 7574459
Drug: Recombinant interferon
Normalized name: Recombinant Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant interferon beta‐1b (alternate-day injections)
Study: 6990950
Drug: Fentanyl 0.125
Normalized name: bupivacaine-fentanyl 0.125%-2 mcg/mL injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl 0.125 mg
Study: 30805949
Drug: NGM282 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: NGM282 3 mg
Study: 19692630
Drug: Metformin (2000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (2000 mg daily, step-up fashion for 8 weeks)
Study: 19692630
Drug: High-dose insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose insulin administration during clamp
Study: 17302186
Drug: Antisymptomatic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antisymptomatic treatment alone
Study: 11133370
Drug: efavirenz (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: efavirenz (600 mg every 24 h) plus indinavir (1000 mg every 8 h)
Study: 11133370
Drug: placebo (every
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo (every 24 h) plus indinavir (800 mg every 8 h)
Study: 8117053
Drug: Lisinopril 20
Normalized name: lisinopril 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril 20 mg + Hydrochlorothiazide 12.5 mg (L/HCTZ)
Study: 8117053
Drug: Captopril 50
Normalized name: captopril 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril 50 mg + Hydrochlorothiazide 25 mg (C/HCTZ)
Study: 2942416
Drug: 0.2 mg
Normalized name: niacin 0.2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg ipratropium powder
Study: 2942416
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg ipratropium powder
Study: 2942416
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg ipratropium powder
Study: 30875607
Drug: FMS training
Normalized name: FM-VP4
DrugBank: FM-VP4 (DB05449)
Approvals — FDA: no, EMA: no, PMDA: no
Description: FMS training (eight weekly 40-min sessions)
Study: 26343743
Drug: Attention control
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Attention control followed by Cognitive Processing Therapy (CPT)
Study: 24229753
Drug: olanzapine plus
Normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: olanzapine plus sertraline
Study: 19520908
Drug: Dexamethasone 8
Normalized name: dexamethasone 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 8 mg twice a day
Study: 19520908
Drug: Tadalafil 10
Normalized name: tadalafil 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tadalafil 10 mg twice a day
Study: 17563395
Drug: Tamoxifen (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen (20 or 30 mg/d)
Study: 15060689
Drug: Single-dose ceftriaxone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose ceftriaxone (50 mg/kg, not exceeding 1 g)
Study: 15060689
Drug: 10-day course
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-day course of amoxicillin-clavulanate (45 mg/kg/day, in 3 divided doses)
Study: 11574373
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of 0.0625% bupivacaine with fentanyl (3 microg/mL)
Study: 11574373
Drug: Preservative‐free saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preservative‐free saline infusion
Study: 2969860
Drug: Cyproterone acetate
Normalized name: cyproterone acetate
DrugBank: Cyproterone acetate (DB04839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyproterone acetate (CPA, 50 mg/day orally)
Study: 2969860
Drug: D‐Trp6 LHRH
Approvals — FDA: no, EMA: no, PMDA: no
Description: D‐Trp6 LHRH (3 mg i.m. once a month)
Study: 1969436
Drug: 2% triclosan
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% triclosan detergent solution
Study: 138480
Drug: 5-FUDR via
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-FUDR via hepatic artery infusion (HAI)
Study: 21649590
Drug: Extended release
Normalized name: Tylenol Extended Release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended release nicotinic acid 1500 mg
Study: 17050586
Drug: Azimilide 75
Normalized name: Azimilide
DrugBank: Azimilide (DB04957)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azimilide 75 mg/day
Study: 9025012
Drug: Inpatient treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inpatient treatment for metabolic control
Study: 8337029
Drug: Hepatitis B
Normalized name: HEPATITIS B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatitis B control vaccine
Study: 28958023
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of SR-STAIRS with SR-1/4MILE or SR-BLOCKS
Study: 29076219
Drug: All treatments
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All treatments (CaCl2, ZG, CaCl2 + ZG, Saline)
Study: 24128148
Drug: Patients receiving
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients receiving methadone‐maintenance treatment for opioid dependence
Study: 17936278
Drug: Determination of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Determination of P(ET)CO(2) once daily
Study: 17936278
Drug: Administration of
Normalized name: IV solutions used in parenteral administration of fluids, electrolytes and nutrients
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of E(2) or P
Study: 16310886
Drug: Gemcitabine 1250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine 1250 mg/m2 on days 1 and 8 + Carboplatin AUC 6 mg/(mLmin) on day 1 (GC)
Study: 16310886
Drug: Vinorelbine 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vinorelbine 30 mg/m2 weekly + Cisplatin 80 mg/m2 on day 1 (VP)
Study: 10375806
Drug: Ciclosporin (Cic)
Normalized name: ciclosporin
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ciclosporin (Cic) 100 mg alone
Study: 10375806
Drug: Ciclosporin (Cic)
Normalized name: ciclosporin
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ciclosporin (Cic) 100 mg with Simvastatin (Sim) 10 mg
Study: 7818264
Drug: Selegiline plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selegiline plus L-dopa-carbidopa
Study: 7818264
Drug: L-dopa-carbidopa alone
Normalized name: α-methyl-L-dopa
DrugBank: Methyldopa (DB00968)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: L-dopa-carbidopa alone
Study: 346488
Drug: E. coli
Normalized name: E. coli antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: E. coli H‐10407 (CFA-positive strain) at a dose of 1 X 10(8)
Study: 346488
Drug: E. coli
Normalized name: E. coli antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: E. coli H‐10407‐P (CFA-negative strain) at a dose of 1 X 10(8)
Study: 11430963
Drug: Raloxifene 60
Normalized name: raloxifene 60 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raloxifene 60 mg per day
Study: 26886210
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose e-cigarettes
Study: 20211530
Drug: Cortisol (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cortisol (20 mg) administered 1h before retention testing
Study: 12174030
Drug: 32 mg
Normalized name: caffeine 32 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 32 mg intravenous methylprednisolone in the morning
Study: 12174030
Drug: 16 mg
Normalized name: escin 16 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 16 mg intravenous methylprednisolone in the morning and 16 mg in the evening
Study: 7843746
Drug: TCV‐116 (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: TCV‐116 (4 mg PO daily)
Study: 7843746
Drug: TCV‐116 (1,
Approvals — FDA: no, EMA: no, PMDA: no
Description: TCV‐116 (1, 2, or 4 mg PO daily)
Study: 418637
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of single and double contrast examinations
Study: 31063679
Drug: Extended antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended antibiotics (72 hours of perioperative antibiotics)
Study: 31063679
Drug: Intraoperative antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraoperative antibiotics only (short antibiotics)
Study: 25844322
Drug: Levetiracetam 62.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levetiracetam 62.5 mg BID
Study: 25844322
Drug: Levetiracetam 125
Normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Levetiracetam 125 mg BID
Study: 25844322
Drug: Levetiracetam 250
Normalized name: levetiracetam 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levetiracetam 250 mg BID
Study: 15385115
Drug: Response to
Normalized name: Besponsa
DrugBank: Inotuzumab ozogamicin (DB05889)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Response to first-line chemotherapy (CR + PR)
Study: 15385115
Drug: No response
Approvals — FDA: no, EMA: no, PMDA: no
Description: No response to first-line chemotherapy (SD + PD)
Study: 12161948
Drug: Biological risk
Normalized name: beremagene geperpavec
DrugBank: Beremagene geperpavec (DB17831)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biological risk assessment
Study: 29181702
Drug: Ursodeoxycholic acid
Normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursodeoxycholic acid (UDCA) therapy
Study: 1671380
Drug: Chlorthalidone (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorthalidone (25 mg) with weight loss diet
Study: 1671380
Drug: Chlorthalidone (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorthalidone (25 mg) with low sodium/high potassium diet
Study: 18931095
Drug: Liraglutide 1.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liraglutide 1.2 mg/day
Study: 19873688
Drug: Glimepiride 8
Normalized name: glimepiride 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glimepiride 8 mg/day
Study: 18940392
Drug: Higher urinary
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher urinary D‐chiro‐inositol excretion
Study: 12535037
Drug: Caudal block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caudal block using bupivacaine 0.15% with ketamine 0.5 mg x kg‐1 (n = 30)
Study: 10395629
Drug: Nitroglycerin ointment
Normalized name: Nitroglycerin Ointment
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitroglycerin ointment (0.2 percent applied twice daily for six weeks)
Study: 10395629
Drug: Both treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatments (crossover patients)
Study: 9332460
Drug: Cisplatin-based combination
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin-based combination chemotherapy (vindesine and cisplatin, mitomycin, vindesine and cisplatin, etoposide and cisplatin alternating with vindesine and mitomycin)
Study: 9332460
Drug: Cisplatin-based combination
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin-based combination chemotherapy (EP/VM arm)
Study: 9332460
Drug: Cisplatin-based combination
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin-based combination chemotherapy (MVP and EP/VM arms)
Study: 8228364
Drug: Large-particle aerosol
Normalized name: Bos taurus large intestine preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Large-particle aerosol (LPA) administration of bivalent cold‐adapted influenza A vaccine
Study: 8228364
Drug: Nose drops
Normalized name: Nose Drops
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nose drops (ND) administration of bivalent cold‐adapted influenza A vaccine
Study: 8228364
Drug: Large-particle aerosol
Normalized name: Bos taurus large intestine preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Large-particle aerosol (LPA) administration
Study: 8228364
Drug: Nose drops
Normalized name: Nose Drops
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nose drops (ND) administration
Study: 25245629
Drug: Infliximab monotherapy
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Infliximab monotherapy
Study: 22571563
Drug: Hypericum perforatum
Normalized name: Hypericum perforatum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypericum perforatum ointment applied twice daily for 4 weeks
Study: 22571563
Drug: Vehicle ointment
Normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle ointment applied twice daily for 4 weeks
Study: 7650234
Drug: Lidocaine (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine (200 mg)
Study: 1672488
Drug: Esmolol (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esmolol (150 mg)
Study: 31770051
Drug: Intradermal (ID)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal (ID) injection of 9 µg hemagglutinin (HA)/strain
Study: 31770051
Drug: Intramuscular (IM)
Normalized name: intramuscular immunoglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular (IM) injection of 15 µg HA/strain
Study: 31770051
Drug: Intradermal (ID)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal (ID) injection of 9 µg HA/strain
Study: 30850406
Drug: Cardiac output-guided
Normalized name: Leonurus cardiaca extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cardiac output-guided haemodynamic therapy algorithm for intravenous fluid and inotropic drug administration during and in the 6 hours following surgery (n=368)
Study: 29021285
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D (511 IU/d from diet and a cholecalciferol supplement) for 10 weeks
Study: 19430307
Drug: AIDSVAX B/E
Approvals — FDA: no, EMA: no, PMDA: no
Description: AIDSVAX B/E HIV‐1 candidate vaccine
Study: 17823649
Drug: risperidone 3
Normalized name: risperidone 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: risperidone 3 mg daily
Study: 15592332
Drug: Grapefruit juice
Normalized name: grapefruit juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grapefruit juice (1.7 mg bergamottin)
Study: 15592332
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg bergamottin
Study: 15592332
Drug: 6 mg
Normalized name: boron 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg bergamottin
Study: 15592332
Drug: 12 mg
Normalized name: pectin 12 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 mg bergamottin
Study: 9765764
Drug: Preoperative chemotherapy
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative chemotherapy with or without postoperative radiotherapy
Study: 10470656
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no preoperative chemotherapy)
Study: 7990020
Drug: root planing
Approvals — FDA: no, EMA: no, PMDA: no
Description: root planing plus a mixture of tetracycline and citric acid‐containing gel (RP + TC‐CAG group)
Study: 7990020
Drug: tetracycline‐containing gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: tetracycline‐containing gel alone (TCG group)
Study: 7990020
Drug: root planing
Approvals — FDA: no, EMA: no, PMDA: no
Description: root planing plus tetracycline‐containing gel (RP + TCG group)
Study: 30428836
Drug: Paracetamol (scheduled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol (scheduled pain treatment)
Study: 30428836
Drug: Placebo (corresponding
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (corresponding placebo treatment)
Study: 24817695
Drug: Antioxidant vitamins
Normalized name: antioxidant vitamins with minerals
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioxidant vitamins C (1 g) and E (400 IU)
Study: 20053349
Drug: Oxandrolone 0.03
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxandrolone 0.03 mg/kg/d